Obituary: Dr Gary Wield
This article was originally published in Scrip
Genactis is saddened to announce that Dr Gary Wield, chair, president and co-Founder of the company has passed away this week after a long battle against serious illness. Despite the sadness and loss, the board and management team will carry on leading Genactis and continue to develop and expand the company as per the vision of its founder. Considering the circumstances, Genactis said it is well prepared and business will be continuing as usual.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.